Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
1996-11-5
|
| pubmed:abstractText |
Islet cell carcinoma (ICC) of the pancreas is a rare, indolent malignancy associated with higher resectability rate and better survival than ductal carcinoma. This retrospective study presents results of surgical treatment from a single institution. From 1985 through 1993 a total of 64 patients (36 men, 28 women) were surgically treated for ICC. Ages ranged from 22 to 80 years (median 55 years) with a median postoperative follow-up of 39 months (range 10-97 months). Of the 64 patients, 30 (47%) had functioning and 34 (53%) nonfunctioning tumors. Gastrinoma (n = 11) followed by glucagonoma (n = 6) and insulinoma (n = 4) were the most common functioning tumors. In the patients undergoing a laboratory study, 67% of the nonfunctioning tumors had elevated peptide hormone levels. Potentially curative resections were performed in 17 patients (26%), palliative procedures in 35 (55%), and exploratory laparotomy alone in 12 (19%). One patient (2%) died within 30 days after operation. Symptomatic improvement was achieved in 96% of patients with a mean duration of 22 months. Three- and five-year survivals were 66% and 49%, respectively. In patients with curative resection, the disease-free survival at 3 years was 53% (95% CI: 32-86%). The presence of diffuse hepatic metastases was a predictor of poor survival at 3 years (74% versus 58%;p = 0.05); there was no statistically significant difference in survival between functioning and nonfunctioning groups (p > 0.1). Although curative resection for ICC is rare, meaningful palliation can be achieved in most patients with rare mortality and acceptable morbidity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0364-2313
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
878-83; discussion 884
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8678966-Adult,
pubmed-meshheading:8678966-Aged,
pubmed-meshheading:8678966-Aged, 80 and over,
pubmed-meshheading:8678966-Carcinoma, Islet Cell,
pubmed-meshheading:8678966-Cause of Death,
pubmed-meshheading:8678966-Disease-Free Survival,
pubmed-meshheading:8678966-Female,
pubmed-meshheading:8678966-Follow-Up Studies,
pubmed-meshheading:8678966-Forecasting,
pubmed-meshheading:8678966-Gastrinoma,
pubmed-meshheading:8678966-Glucagonoma,
pubmed-meshheading:8678966-Humans,
pubmed-meshheading:8678966-Insulinoma,
pubmed-meshheading:8678966-Laparotomy,
pubmed-meshheading:8678966-Liver Neoplasms,
pubmed-meshheading:8678966-Male,
pubmed-meshheading:8678966-Middle Aged,
pubmed-meshheading:8678966-Palliative Care,
pubmed-meshheading:8678966-Pancreatic Neoplasms,
pubmed-meshheading:8678966-Retrospective Studies,
pubmed-meshheading:8678966-Survival Rate,
pubmed-meshheading:8678966-Treatment Outcome
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Islet cell carcinoma of the pancreas.
|
| pubmed:affiliation |
Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
|
| pubmed:publicationType |
Journal Article
|